Inspirex™ Lung
End-stage lung disease
PreclinicalActive
Key Facts
About Xylyx Bio
Xylyx Bio is a private, pre-revenue biotech company developing a novel solution to the global organ shortage crisis through its proprietary XC™ Platform. The platform utilizes xenogeneic cross-circulation with a porcine bioreactor to rehabilitate and bioengineer discarded human donor organs into functional whole organ grafts, branded as Inspirex™. Its pipeline includes lung, liver, kidney, and heart graft programs, with the lung and liver in preclinical stages and the kidney and heart in prototype development. The company is supported by foundation grants and is focused on advancing its lead programs toward clinical trials.
View full company profileTherapeutic Areas
Other End-stage lung disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Xenolung | United Therapeutics | Preclinical |